ArriVent BioPharma, Inc. Common Stock (AVBP) Financials

$16.61

north_east
$0.19 (1.16%)
Day's range
$15.47
Day's range
$17.05
$0$0-$20M-$20M-$40M-$40M-$60M-$60M-$80M-$80M-$100M-$100MEarning202120212022202220232023202420245%5%4%4%3%3%2%2%1%1%0%0%Profit Margin
Profit Margin
Revenue
Earnings

AVBP Income statement / Annual

Last year (2024), ArriVent BioPharma, Inc. Common Stock's total revenue was $0.00, and the percentage change from the previous year is not available. In 2024, ArriVent BioPharma, Inc. Common Stock's net income was -$80.49 M. See ArriVent BioPharma, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Operating Revenue $0.00 $0.00 $0.00 $0.00
Cost of Revenue $0.00 $0.00 $0.00 $0.00
Gross Profit $0.00 $0.00 $0.00 $0.00
Gross Profit Ratio 0 0 0 0
Research and Development Expenses $79.00 M $64.88 M $30.43 M $6.43 M
General & Administrative Expenses $15.30 M $9.71 M $6.47 M $3.02 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 -$753,999.00
Selling, General & Administrative Expenses $15.30 M $9.71 M $6.47 M $2.26 M
Other Expenses $0.00 $0.00 $0.00 $0.00
Operating Expenses $94.31 M $74.59 M $36.91 M $8.70 M
Cost And Expenses $0.00 $74.59 M $36.91 M $8.70 M
Interest Income $13.82 M $5.26 M $0.00 $0.00
Interest Expense $0.00 $0.00 $0.00 $0.00
Depreciation & Amortization $0.00 $0.00 $36.91 M $11.59 M
EBITDA $0.00 -$74.59 M -$36.91 M -$51.61 M
EBITDA Ratio 0 0 0 0
Operating Income Ratio 0 0 0 0
Total Other Income/Expenses Net $0.00 $5.26 M $0.00 -$60.11 M
Income Before Tax -$80.49 M -$69.33 M -$36.91 M -$51.61 M
Income Before Tax Ratio 0 0 0 0
Income Tax Expense $0.00 $0.00 -$36.91 M -$11.59 M
Net Income -$80.49 M -$69.33 M -$36.91 M -$51.61 M
Net Income Ratio 0 0 0 0
EPS -2.56 -2.17 -1.1 -1.54
EPS Diluted -2.56 -2.17 -1.1 -1.54
Weighted Average Shares Out $31.47 M $31.96 M $33.49 M $33.49 M
Weighted Average Shares Out Diluted $31.47 M $31.96 M $33.49 M $33.49 M
Link